Vancouver, BC / ACCESSWIRE / Wednesday June 11, 2014 / Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTC PINK: ATTBF) (CSE: ATT), through its wholly owned Washington subsidiary Abattis Bioceuticals International Inc. is pleased to announce Dr. Sexton, CSO of Phytalab LLC in Kirkland, WA, will have an oral presentation at the upcoming 24th Annual International Cannabinoid Research Society (ICRS) meeting in Baveno Italy. Dr. Sexton has been a member of the ICRS since 2007 and has previously presented for the ICRS. She served on the program committee for this 2014 symposium on Cannabinoids. Her talk is entitled “A MEDICAL ETHNOGRAPHIC REPORT OF CANNABIS USE IN PEDIATRIC INTRACTABLE EPILEPSY (IE) PATIENTS” and will be presented during a session on “CNS and Psychiatric Issues”, June 30th. Dr. Sexton will also be chairing a session with Luciano di Petrocellis entitled ” Beyond THC: Cannabidiol and Other Components.” The five-day conference is the meeting for a group of over 500 active researchers in all fields of the cannabinoids and related bioactive lipids. Dr. Sexton commented “I am honored that ICRS President Ethan Russo gave me the opportunity to participate in this historic organization, and proud to have earned the opportunity to discuss research with a fabulous collection of thinkers”.
The company is also pleased to announce PhytaLab is in the process of submission the extensive paperwork and data collection necessary for receiving provisional status for testing of Cannabis and related products under I502 in Washington State. Application for the certification by the State enables Phytalab to expand testing for the medical Cannabis market to testing in the new marketplace.
Mike Withrow, CEO of Abattis stated “We are proud of the work Dr. Sexton and the team at Phytalab.com are doing. The team is on target and meeting all of their milestones.”
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.
About Phytalab LLC
PhytaLab is an industry leader with regard to experience and validation know-how. We ensure that our instruments are calibrated daily and use internal standards to maximize the accuracy of the potency measurement. PhytaLab utilizes high-performance liquid chromatography (HPLC) to separate and quantify the relevant cannabinoids in client samples. It is the most accurate, optimal and straightforward method for analysis of the authentic plant compounds, including acidic and neutral forms. PhytaLab has taken great care to maximize HPLC resolution so there is no overlap of compounds guaranteeing accurate potency measurements. For more information, visit the Company’s website at: www.phytalab.com
ON BEHALF OF THE BOARD
President & CEO
For further information, contact the Company’s CEO, Michael Withrow at (778) 896-6536
or at email@example.com.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words “anticipate“, “continue“, “estimate“, “expect“, “may“, “will“, “project“, “should“, “believe“ and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company‘s Management‘s Discussion and Analysis under the Company‘s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.
SOURCE: Abattis Bioceuticals Corp